



14 July 2021

ReNeuron Group plc
(“ReNeuron” or the “Company”)

Board Change

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Barbara Staehelin has joined the Board as senior independent Non-Executive Director with immediate effect.

Ms. Staehelin’s career in the international life sciences and technology sectors spans over 30 years and includes consulting, CEO and Chair roles. She has led and co-founded four life science companies and is currently on the Board as President of the Audit and Risk Committee and a member of the Investment Committee at Assura Group, which operates in the health insurance sector and which is headquartered in Switzerland. Ms. Staehelin’s background is in biochemistry and until 2006, she was a member of the Global Executive Committee of Roche Diagnostics.

Ms. Staehelin holds a Directors Certificate from Harvard University, USA as well as executive education in new concepts for boards from University St. Gallen, Switzerland, health economy from the European School for Health Economics, France and an MBA from INSEAD Fontainebleau, France.

Iain Ross, Chairman of ReNeuron, commented: *“I am delighted to welcome Barbara to the ReNeuron Board as a Non-Executive Director. She brings a wealth of market development experience in the medical services and biotech sectors and a strong track record in corporate governance. My colleagues and I look forward to working with her during this transformational time for ReNeuron.”*

Disclosures in accordance with the AIM Rules

Barbara Regina Staehelin, 58, is, or has been, a director or partner of the following companies or partnerships during the past five years:

Current Partnerships and Directorships:

Axicos AG
Assura Holding SA
Assura SA
Assura-Basis SA
Figeas SA
ABC Invest & Medical GmbH
Dybly AG
Ava AG

Prior Partnerships & Directorships:

Keires AG

In 2009, Ms Staehelin was appointed as turnaround CEO of SIRS-Lab GmbH, a molecular diagnostics company headquartered in Germany. Having successfully led one funding round and the completion of a clinical trial, in July 2012, Ms Staehelin resigned from her position and worked her notice period. On 1 March 2013, as a result of an inability to raise additional capital, the company entered into a Court ordered liquidation and then was dissolved on 3 November 2013.

In 1997, Ms Staehelin became Chairman of GetWellness AG which was voluntarily dissolved in 2006 in a solvent wind-up and the resulting corporate entity was then put into liquidation.

Ms. Staehelin has no holding in ReNeuron.

There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

ENDS

Contacts:

ReNeuron

Olav Hellebø, Chief Executive Officer

www.reneuron.com/investors

Via Walbrook PR

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

Allenby Capital Limited (Joint Broker)

James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)

+44 (0)20 3328 5656

Walbrook PR (Media & Investor Relations)

Paul McManus, Alice Woodings

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com